在第三期试验中,AstraZeneca的Tozorakimab显示显著降低了COPD. AstraZeneca's Tozorakimab shows significant COPD reduction in Phase III trial.

亚博体育app下载公司报告称,其实验性药物Tozorakimab在COPDIII期试验中实现了主要目标,显示出恶化症的统计显著减少. AstraZeneca reports that its experimental drug Tozorakimab met its primary goal in a Phase III COPD trial, showing a statistically significant reduction in exacerbations. 治疗在不同患者群体中表现出有效性,并且通常耐受良好. The treatment demonstrated effectiveness across diverse patient groups and is generally well tolerated. 亚洲医计划将数据提交监管机构,并在即将举行的医学会议上提出研究结果. AstraZeneca plans to submit the data to regulators and present findings at an upcoming medical meeting.